Please ensure Javascript is enabled for purposes of website accessibility

Stanley Erck

President & CEO
Novavax

Stanley Erck has been president and CEO of the Gaithersburg-based biotechnology company Novavax since April 2011.

Prior to his roles in Novavax, Erck was president and CEO of IOMAI Corporation, leading the company through an initial public offering and a merger with the Austrian vaccine maker Intercell as it developed a late-stage infectious disease product.

Erck was also the president and CEO of Procept, a publicly traded immunology company; the vice president of corporate development at Integrated Genetics (now Genzyme); and in management positions within Baxter International.

He sits on the board of directors of MaxCyte, Inc. Erck earned his undergraduate degree from the University of Illinois and an MBA from the University of Chicago Booth School of Business.

In the face of the pandemic, Novavax was transformed and made the decision to focus virtually all of its efforts on the most pressing health challenge in recent times – developing a COVID-19 vaccine.

“Leveraging innovative technology and a novel vaccine development platform, we were one of a handful of companies worldwide to rapidly develop and demonstrate strong efficacy and a robust safety profile for a protein-based COVID-19 vaccine candidate,” he said. “Success has been demonstrated across the board, including in two large-scale Phase 3 clinical trials.”

Being based in Maryland’s bio-innovation corridor benefits Novavax every day, Erck said, as does being close to job candidates from a strong educational system.

“Novavax is building its new headquarters in Gaithersburg, Maryland, because of these advantages,” he said.